Brinter
Finnish bioprinting hardware company developing modular multi-material 3D bioprinting systems for tissue engineering, biomedical research, and regenerative medicine implants.
- CEO / Founder
- Tomi Alapaattikoski
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $3.52M
- Latest Round
- Seed
- Key Investors
- Innovestor; Athensmed; Plug and Play Tech Center; Techstars; Winston Starts; Business Finland; European Union; European Space Agency (ESA)
Technology & Products
Key Products
Modular multi-material 3D bioprinters (Brinter One/Brinter Core), 3D bioprinted regenerative tissue implants for orthopedic and aesthetic applications
Technological Advantage
Modular platform enabling multiple bioprinting modalities in one system
Patent position
Brinter filed 18 patent families across all years, compared with 51 for Aspect Biosystems and 5 for Allevi. AMPulse analysis
- Filing momentum
- 10 families filed 2022–2024, 4 in 2019–2021
- Filed in
- US 44%EP 28%WO 22%CN 6%
- Named competitors, AM patent families
- Aspect Biosystems 51Allevi 5
18 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.
Differentiation
Value Proposition
Modular multi-material 3D bioprinting platform for scalable advanced tissue manufacturing and regenerative implants
How They Differentiate
Modular multi-material approach with scalable bioprinting platform for regenerative tissue implant manufacturing
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, hospitals
Industry Verticals
Biotechnology, Pharmaceuticals, Research, Healthcare, Manufacturing
Competitors
Desktop Health, Aspect Biosystems, Allevi
Growth & Milestones
Growth Metrics
Active in 10+ countries including Germany and UK; revenue estimated $1–10M range (LeadIQ)
Major Milestones
Founded (3DTech/Brinter origin); 2020: Launched Brinter brand; 2021: €1.2M seed funding (Innovestor, Athensmed); 2023: Pre-Seed $750K; Selected by Redwire Space NV as bioprinter supplier for ESA ISS 3D-BioSystem Facility (Advanced Tissue Manufacturing project); Collaboration established with UPM Biomedicals
Notable Customers
Research institutions; Pharmaceutical companies; Redwire Space NV / European Space Agency (bioprinter supplier for ISS Advanced Tissue Manufacturing project)
AM patents
AM-relevant patents linked to this company.
- Patents
- 18
- Granted
- 7
- Families
- 18
Leading domains: process (18), equipment (12), material (7)
Filings by year: 2023: 1 · 2022: 9 · 2021: 4 · 2018: 4
- SYSTEM AND METHOD FOR PERFORMING QUALITY ANALYSIS FOR MULTIDIMENSIONAL PRINTING20230091230 · US
- SYSTEM AND METHOD FOR PERFORMING QUALITY ANALYSIS FOR MULTIDIMENSIONAL PRINTING4405160 · EP
- SYSTEM AND METHOD FOR CONTROLLING RATE OF FLOW OF PRINTING MATERIAL4633955 · EP
- MULTI-MATERIAL FLUIDIC PRINTING SYSTEM AND METHOD OF PRINTING4568825 · EP
- SYSTEM AND METHOD FOR CONTROLLING RATE OF FLOW OF PRINTING MATERIAL2024126890 · WO
Funding rounds
- Pre-Seed$750K2023-02Source: Crunchbase
- Seed~$1.3M (€1.2M)2021-06Lead: Innovestor · Source: ArcticStartup / Tracxn